Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 11,285,720 | 10,280,080 | 11,424,970 | 11,520,500 | 10,666,100 |
| Cost of Goods | 3,041,198 | 2,526,563 | 3,515,934 | 3,043,558 | 2,891,574 |
| Gross Profit | 8,244,521 | 7,753,515 | 7,909,035 | 8,476,943 | 7,774,528 |
| Operating Expenses | 7,599,170 | 4,664,260 | 6,438,117 | 4,982,396 | 5,073,182 |
| Operating Income | 645,550 | 3,089,817 | 1,471,853 | 3,495,105 | 2,701,919 |
| Interest Expense | 244,262 | 225,033 | 249,520 | 225,099 | 245,750 |
| Other Income | 73,816 | 24,256 | 51,620 | 40,436 | 64,108 |
| Pre-tax Income | 475,103 | 2,889,040 | 1,273,953 | 3,310,442 | 2,520,277 |
| Income Tax | -267,078 | 410,988 | 300,778 | 420,545 | 321,880 |
| Net Income Continuous | 742,181 | 2,478,052 | 973,176 | 2,889,898 | 2,198,398 |
| Minority Interests | 158,368 | 137,445 | 121,507 | 176,575 | 271,127 |
| Net Income | $583,814 | $2,340,607 | $851,668 | $2,713,323 | $1,927,271 |
| EPS Basic Total Ops | 0.29 | 1.16 | 0.43 | 1.35 | 0.95 |
| EPS Basic Continuous Ops | 0.37 | 1.23 | 0.49 | 1.43 | 1.08 |
| EPS Diluted Total Ops | 0.29 | 1.15 | 0.41 | 1.32 | 0.94 |
| EPS Diluted Continuous Ops | 0.37 | 1.22 | 0.46 | 1.41 | 1.07 |
| EPS Diluted Before Non-Recurring Items | 1.36 | 1.24 | 0.68 | 1.48 | 1.23 |
| EBITDA(a) | $3,716,460 | $3,713,710 | $857,035 | $4,514,233 | $4,312,510 |